70
Ita Armyanti Farmakologi PSPD FK UNTAN Jun 28, 2022 1 Muskuloskeletal2013

(4). NSAID-musket2013

Embed Size (px)

DESCRIPTION

Must to know

Citation preview

Page 1: (4). NSAID-musket2013

Ita ArmyantiFarmakologi PSPD FK

UNTAN

Apr 28, 2023 1Muskuloskeletal2013

Page 2: (4). NSAID-musket2013

1. Sebutkan 2 contoh obat yang termasuk dalam NSAIDs, beserta mekanisme kerjanya

2. Sebutkan 2 efek samping yg sering tjd akibat pemakaian NSAIDs

3. Sebutkan 2 indikasi NSAIDs

Apr 28, 2023muskuloskeletal2012 2

Page 3: (4). NSAID-musket2013

Menghambat sintesis PG : produk dr COX

Prostaglandins are arachidonic acid metabolites.

Arachidonic acid is a fatty acid released from membrane phospholipids by the actions of phospholipase A2It can also be released by the combination phospholipase C and diglyceride lipase.

Apr 28, 2023 3muskuloskeletal2012

Page 4: (4). NSAID-musket2013

Apr 28, 2023muskuloskeletal2012 4

Page 5: (4). NSAID-musket2013

1. Cycloogygenase-1 (Cox-1):• It is constitutively expressed• Widely distributed and has a

“housekeeping” function. e.g gastric cytoprotection

2. Cycloogygenase-2 (Cox-2):• Inducible• Is an immediate early response

gene product in inflammatory & immune cells

Apr 28, 2023 5muskuloskeletal2012

Page 6: (4). NSAID-musket2013

Expression is 10-18 fold stimulated by growth factors, tumor promoters, cytokines and lipopolysaccaride endotoxin.

Inhibited by dexamethasone Involved in normal development Involved in vascular prostacyclin

production.

Apr 28, 2023 6muskuloskeletal2012

Page 7: (4). NSAID-musket2013

Membrane Phospholipids

Arachidonic acid

Cyclic endoperoxides

Phospholipase A2

Phospholipase C

Diglyceride lipase

CyclooxygenaseLipooxygenase

LTs

PGI2 TXA2

PGD2PGE2

PGF2α

PGI synthase Thromboxane synthase

PGE synthase

PGDsynthase

PGE9-KetoreductaseApr 28, 2023 7muskuloskeletal2012

Page 8: (4). NSAID-musket2013

LTA4

LTB4 LTC4

LTD4

LTE4

1. Phagocyte activation

2. ChemotaxisBronchoconstriction

Apr 28, 2023 8muskuloskeletal2012

Page 9: (4). NSAID-musket2013

PGI2:1. Vasodilation2. Inhibition of platelet aggregation3. Bronchodilation4. Glomerular filtration TXA2:1. Vasoconstriction2. Stimulation of platelet aggregation3. Is a smooth muscle mitogen4. Intrarenal vasoconstriction during

inflammatory conditions of the kidney

Apr 28, 2023 9muskuloskeletal2012

Page 10: (4). NSAID-musket2013

PGE2:1. Vasodilation2. Patency of ductus arteriosus3. Bronchodilation4. Uterine contraction & dysmenorrhea5. Cervical ripening6. Decreased gastric acid secretion7. Pain sensitization8. Increased body temperature9. Stimulate longitudinal muscle in GIT10. Increase glomerular filtration

Apr 28, 2023 10muskuloskeletal2012

Page 11: (4). NSAID-musket2013

PGF2α:1. Vasoconstriction2. Bronchoconstriction3. Uterine contraction4. Aqueous humor drainage5. Contracts circular muscle in GIT PGD2:1. Bronchoconstriction2. Vasodilation or vasoconstriction3. Natural sleep

Apr 28, 2023 11muskuloskeletal2012

Page 12: (4). NSAID-musket2013

1. Alprostadil (PGE1 analogue):Used to maintain patency of the ductus arteriosus in infants with congenital heart disease – waiting for surgical correction

2. Carboprost (PGF2α analogue):a. To terminate pregnancyb. To control refractory postpartum bleeding

Apr 28, 2023 12muskuloskeletal2012

Page 13: (4). NSAID-musket2013

3. Misoprostol (PGE1 analogue):a. Used in combination with NSAIDs to decrease gastric acid secretion & to inhibit ulcerationb. Induction of laborc. Enhancing cervical ripeningd. Induction of abortion Associated with increased risk of uterine rupture and perforation

Apr 28, 2023 13muskuloskeletal2012

Page 14: (4). NSAID-musket2013

4. Dinoprostone (PGE2 analogue):Causes uterine contractions and is used to induce abortion during the second trimester and to empty the uterus following fetal death, missed abortion or benign hydatidiform mole.

5. Epoprostenol (PGI2 analogue):For primary pulmonary hypertension

6. Latanoprost (PGF2α analogue):For glaucoma

Apr 28, 2023 14muskuloskeletal2012

Page 15: (4). NSAID-musket2013

Involves the release of a number of mediators

Results in pain and tissue destruction

Treatment involves:1. Relief of pain2. Slowing tissue damage or3. Arresting tissue damage

Apr 28, 2023 15muskuloskeletal2012

Page 16: (4). NSAID-musket2013

Analgesic-antipyretic-antiinflammatory Drugs.

Chemically diverse group of compounds

All are weak organic acids except nabumetone which is a prodrug metabolized to an acidic active drug

Most are highly metabolizedApr 28, 2023 16muskuloskeletal2012

Page 17: (4). NSAID-musket2013

Broad range of pharmacokinetic characteristics

Most are highly ( > 98%) protein-bound

Used to treat muscle strain, tendinitis, bursitis, rheumatoid arthritis, osteoarthritis & ankylosing spondylitis

Antiinflammatory action is mediated via inhibition cycloxygenase-2 and thus PG synthesis

Apr 28, 2023 17muskuloskeletal2012

Page 18: (4). NSAID-musket2013

Most are reversible inhibitors of Coxs,except aspirin which irreversibly acetylates the active site of the enzyme1. Celecoxib, rofecoxib & valdecoxib are

selective Cox-2 inhibitors2. Aspirin, indomethacin, piroxicam &

sulindac are more effective on Cox-13. Ibuprofen & meclofenamic acid

inhibit the 2 isozymes equally

Apr 28, 2023 18muskuloskeletal2012

Page 19: (4). NSAID-musket2013

Is the prototype NSAID Use for inflammatory conditions is

now rare Mainly used as antiplatelet drugPharmacokinetics: Acetylsalicylic acid is rapidly

absorbed from the stomach and upper intestine

Is rapidly hydrolyzed to acetic acid and salicylate by esterases in tissues and blood

Apr 28, 2023 19muskuloskeletal2012

Page 20: (4). NSAID-musket2013

Salicylate is bound to albumin and binding is saturable

Eliminated by metabolism and elimination is zero-order (saturable)

t½ is dose-dependant:600 mg / day 3-5 hours> 3.6 g / day 12-16 hours

Alkalinization of urine increases rate of excretion of salicylates

Apr 28, 2023 20muskuloskeletal2012

Page 21: (4). NSAID-musket2013

A. Antiinflammatory: Nonselective inhibitor of both Cox

izozymes Nonacetylated salicylates may work as

oxygen radical scavengers Interfere with chemical mediators of

the kallikrein system, thus, inhibiting granulocyte adherence to the damaged vasculature, stabilizing lysosomes and inhibiting the chemotaxis of polymorphonuclear leukocytes and macrophages. Dose > 3.6 g

Apr 28, 2023 21muskuloskeletal2012

Page 22: (4). NSAID-musket2013

B. Analgesic effects:Reduces pain of mild-to-moderate severity through its effects on inflammation. It may also inhibit pain stimuli at a subcortical site

Apr 28, 2023 22muskuloskeletal2012

Page 23: (4). NSAID-musket2013

C. Antipyretic effects: Reduces elevated body temperature Antipyretic effect is probably mediated

by both COX inhibition in the CNS and inhibition of IL-1 (released from macrophages during inflammation . Dose ~ 600 mg

D. Antiplatelet effects: At single low dose (81 mg) daily due to

irreversible inhibition of platelet COX Effect lasts for the life of platelet (8-10

days)Apr 28, 2023 23muskuloskeletal2012

Page 24: (4). NSAID-musket2013

1. Gastric upset, peptic ulceration & upper GI bleeding. Fecal blood loss Iron deficiency anemia (less with COX-2 inhibitors)

2. Salicylism: At high & chronic dose.Vomiting, tinnitus, decreased hearing, deafness, vertigo, headache, nervousness, confusion, retinal disturbances

Apr 28, 2023 24muskuloskeletal2012

Page 25: (4). NSAID-musket2013

3. Toxic doses:• Respiratory alkalosis due to

hyperpnea through a direct effect on the medulla

• Followed by metabolic acidosis due to salicylate accumulation

• Respiratory depression• Cardiac toxicity• Glucose intolerance

Apr 28, 2023 25muskuloskeletal2012

Page 26: (4). NSAID-musket2013

4. Uric acid retention at doses of 2 g or less dailyUric acid excretion at daily doses of 4 g or more

5. Renal function impairment, fluid retention, interstitial nephritis, papillary necrosis

6. Elevation of liver enzymes, hepatic necrosis, cholestasis, hepatitis & Reye’s syndrome in children with febrile illness

Apr 28, 2023 26muskuloskeletal2012

Page 27: (4). NSAID-musket2013

7. Bleeding8. Allergic reactions: rash, asthma,

nasal polyps & anaphylaxis9. Hyperthermia: due to uncoupling

of oxidative phosphorylation10. Electrolyte disturbances11. Inhibition of uterine contractions

– delayed labor, low birth weight, premature closure of ductus arteriosus

12. Photosensitivity, toxic epidermal necrolysis

Apr 28, 2023 27muskuloskeletal2012

Page 28: (4). NSAID-musket2013

Very good analgesic and antipyretic

Used for:1. Musculoskeletal disorders PO,

IM2. Renal colic IM3. Dysmenorrhea IM4. Solar keratosis

TopicalApr 28, 2023 28muskuloskeletal2012

Page 29: (4). NSAID-musket2013

Salicylic acid derivative Zero-order kinetics Claimed to be particularly useful

for cancer pain with bone metastasis

Pain following dental surgery

Apr 28, 2023 29muskuloskeletal2012

Page 30: (4). NSAID-musket2013

Can be used orally or topically Less sodium and water retention

than others Less frequent GIT irritation or

bleeding AE : Aseptic meningitis particularly

in patients with SLE has been reported

Other adverse effects are similar Useful analgesic & antiinflammatory

Apr 28, 2023 30muskuloskeletal2012

Page 31: (4). NSAID-musket2013

May also inhibit phospholipases A & CReduces neutrophil migrationDecreases T cell and B cell proliferation

Probenecid prologs its half-life by inhibiting its biliary and renal secretion

Used in:1. Rheumatic conditions: Gout and

ankylosing spondylitis2. Patent ductus arteriosus Adverse effects occur in one third of

patients

Apr 28, 2023 31muskuloskeletal2012

Page 32: (4). NSAID-musket2013

Similar but more severe than other NSAIDs.

Headache (20%) + dizziness, confusion and depression

Psychosis, hallucinations Aplastic anemia, thrombocytopenia Hyperkalemia Diarrhea Pancreatitis

Apr 28, 2023 32muskuloskeletal2012

Page 33: (4). NSAID-musket2013

Has significant analgesic efficacy, used to replace morphine

Can be given IM, IV, PO Adverse effects similar to other

NSAIDs More renal toxicity

Apr 28, 2023 33muskuloskeletal2012

Page 34: (4). NSAID-musket2013

Prodrug t½ > 24 hours Less toxic to the stomach Adverse effects similar to NSAIDs May cause photosensitivity

Apr 28, 2023 34muskuloskeletal2012

Page 35: (4). NSAID-musket2013

Also inhibits polymorphonuclear leukocyte migration, decreases oxygen radical production and inhibits lymphocytes function

t½ very long ~ 57 hours Used for rheumatic conditions More toxic than other NSAIDs

Apr 28, 2023 35muskuloskeletal2012

Page 36: (4). NSAID-musket2013

Is a sulfoxide prodrug Metabolized into the active sulfide

metabolite Undergoes enterhepatic cycling,

like many other NSAIDs Indications similar to other NSAIDs

+1. Suppression of familial intestinal

polyposis2. May prevent development of

colon, breast and prostate cancerApr 28, 2023 36muskuloskeletal2012

Page 37: (4). NSAID-musket2013

Adverse effects similar to NSAIDs +1. Less nephrotoxic ( reoxidized to

the inactive prodrug in the kidney2. Steven Johnson syndrome,

epidermal necrolysis3. Thrombocytopenia,

agranulocytosis4. Nephrotic syndrome and reversible

renal failure5. Cholestatic hepatic damage

Apr 28, 2023 37muskuloskeletal2012

Page 38: (4). NSAID-musket2013

Celecoxib, Rofecoxib, Etoricoxib 10-20 X more selective

Meloxicam – preferential selection

Do not affect the constitutive form of COX significantly

Also has analgesic, antipyretic & antiinflammatory properties

Fewer GI adverse effectsApr 28, 2023 38muskuloskeletal2012

Page 39: (4). NSAID-musket2013

No impact on platelet aggregation, no cardiovascular protection

Renal toxicity similar to COX-1 inhibitors

Higher incidence of cardiovascular thrombotic events, hypertension, death from cardiac causes

Some of them were withdrawn from the market because of this adverse effect

Apr 28, 2023 39muskuloskeletal2012

Page 40: (4). NSAID-musket2013

1. GI bleeding and history of peptic ulceration

2. Advanced age, poor health, long duration of treatment & heavy alcohol use

3. Renal Impairment4. Heart failure, edema5. Hypertension6. Hypersensitivity reactions to

salicylates7. Bronchial asthma8. Pregnancy (?)

Apr 28, 2023 40muskuloskeletal2012

Page 41: (4). NSAID-musket2013

1. Corticosteroids: increased toxicity2. Biphosphonates: enhance GIT

irritation3. Anticoagulants including warfarin

(CYP2C9)4. Methotrexate: NSAIDs can decrease

its clearance severe hematologic and GI toxicity

5. Increase nephrotoxicity of aminoglycosides, amphotericin B, and other nephrotoxic agents

Apr 28, 2023 41muskuloskeletal2012

Page 42: (4). NSAID-musket2013

NSAIDs often offer symptomatic relief, reduce inflammation and pain and preserve function but have little effect on bone and cartilage destruction

DMARDs slow the progression and arrest the disease over 6 weeks to 6 months

Apr 28, 2023 42muskuloskeletal2012

Page 43: (4). NSAID-musket2013

Methotrexate Chlorambucil Cyclophosphamide Azathioprine Cyclosporine Mycophenolate mofetil

May be discussed later with anticancer drugs and immunosuppressants

Apr 28, 2023 43muskuloskeletal2012

Page 44: (4). NSAID-musket2013

Used mainly in the treatment of malaria and will be discussed more there

Antiinflammatory mechanism is unknown:

1. Suppression of T lymphocyte response to mitogens

2. Decreased leukocyte chemotaxis3. Stabilization of lysosomal enzymes4. Inhibition of DNA & RNA synthesis5. Trapping of free radicals

Apr 28, 2023 44muskuloskeletal2012

Page 45: (4). NSAID-musket2013

Extensively distributed to melanin-containing tissues

Indications:Rheumatoid arthritis: Takes 3-6 months to obtain a response

Adverse effects:1. Ocular toxicity2. Nightmares3. Dyspepsia

Apr 28, 2023 45muskuloskeletal2012

Page 46: (4). NSAID-musket2013

Rarely used because of toxicity Aurothiomalate and

Aurothioglucose IM Auranofin PO Mechanism of Action:

Alteration of morphology and function of macrophages: Inhibition of chemotactic factor-1, interleukin-8 and interleukin-1B production and vascular endothelium growth factor

Apr 28, 2023 46muskuloskeletal2012

Page 47: (4). NSAID-musket2013

Mechanism of Action (contd):IM gold compounds also alter lysosomal enzyme activity, reduce histamine release, inactivate the first component of complement and suppress phagocytic activity of polymorphonuclear leukocytesAuranofin also inhibits the release of PGE2 and LTB4.

Apr 28, 2023 47muskuloskeletal2012

Page 48: (4). NSAID-musket2013

Tends to concentrate in synovial membranes, liver, kidney, spleen, lymph nodes & bone marrow

t½ ~ 1 year Excreted in urine and feces Indications:

Active rheumatoid arthritis slows progression of the disease

Apr 28, 2023 48muskuloskeletal2012

Page 49: (4). NSAID-musket2013

Adverse effects:1. Pruritic skin rash and eosinophilia2. Stomatitis and metallic taste3. Thrombocytopenia, leukopenia,

pancytopenia and aplastic anemia4. Proteinuria, nephrotic syndrome5. Enterocolitis & cholestasis6. Peripheral neuropathy7. Pulmonary infiltrates8. Sweating, flushing & headache9. Corneal deposits

Apr 28, 2023 49muskuloskeletal2012

Page 50: (4). NSAID-musket2013

TNF-α and IL-1 are among the most important inflammatory cytokines

Are produced mainly by cells of the monocyte-macrophage lineage

Work in concert to stimulate inflammatory responses such as pain, fever and recruitment of lymphocytes

They also induce production of many other inflammatory mediators and contribute to tissue damage seen in chronic inflammation

Apr 28, 2023 50muskuloskeletal2012

Page 51: (4). NSAID-musket2013

Adalimumab, Infliximab, Etanercept Indicated for rheumatoid arthritis Main adverse effect is flare up of

macrophage-dependent infections such as tuberculosis and other opportunistic infections

Increased incidence of malignancies ???

Apr 28, 2023 51muskuloskeletal2012

Page 52: (4). NSAID-musket2013

Mechanism of action: It is converted to its active

metabolite in the intestine and plasma rapidly.

It inhibits dihydroorotate dehydrogenase reduced RNA synthesis and arrest of stimulated cells in G1 phase of cell growth Inhibition of T cell proliferation and production of autoantibodies by B cells

Apr 28, 2023 52muskuloskeletal2012

Page 53: (4). NSAID-musket2013

Completely absorbed after PO administration, t½ ~ 19 days

Indications: Rheumatoid arthritis, inhibits bone damage

Adverse effects:1. Diarrhea and elevation of liver

enzymes2. Mild alopecia3. Weight gain4. Increased blood pressure5. Leukopenia and thrombocytopenia6. Contraindicated in pregnancy

Apr 28, 2023 53muskuloskeletal2012

Page 54: (4). NSAID-musket2013

Analgesic-antipyretic but not antiinflammatory

Weak COX-1 and COX-2 inhibitor in peripheral tissues

Appears to inhibit COX-3 in the brain Pharmacokinetics:

Well absorbed following PO administrationMetabolized to glucuronide and sulfate conjugatest½ ~ 2-3 hours

Apr 28, 2023 54muskuloskeletal2012

Page 55: (4). NSAID-musket2013

Indications:1. Mild-to-moderate pain2. FeverAdverse effects: Safe at therapeutic doses Large doses dizziness, excitement &

disorientation Hepatic toxicity with centrilobular

necrosis due to accumulation of the metabolite N-acetyl-benzoquinoneimine.

May also produce acute renal tubular necrosis

Lethal dose 15 grams. Antidote: sulfhydryl (-SH) containing

agents such as N-acetylcysteineApr 28, 2023 55muskuloskeletal2012

Page 56: (4). NSAID-musket2013

Gout is a familial metabolic disease characterized by recurrent episodes of acute arthritis.

It is due to deposition of monosodium urate crystals in joints and cartilage

Usually associated with high serum levels of uric acid

Uric acid calculi may deposit in the kidney as part of the disease

Aims of treatment:1. Relief of acute gouty attack2. Prevention of recurrent gouty episodes

Apr 28, 2023 56muskuloskeletal2012

Page 57: (4). NSAID-musket2013

Mechanism of action:Binds the intracellular protein, tubulin, preventing its polymerization into microtubules inhibition of leukocyte migration and phagocytosis and cell mitosis.

It also inhibits the formation of LTB4

Apr 28, 2023 57muskuloskeletal2012

Page 58: (4). NSAID-musket2013

Pharmacodynamics:It rapidly relieves the pain and inflammation of gouty arthritis in 12-24 hoursNo direct analgesic effectNo effect on uric acid

Pharmacokinetics:Absorbed rapidly after oral administration and eliminated in urine and feces as metabolites

Apr 28, 2023 58muskuloskeletal2012

Page 59: (4). NSAID-musket2013

Therapeutic uses:1. Acute gouty arthritis2. Acute Mediterranean fever3. Sarcoid arthritis4. Hepatic cirrhosisAdverse Effects:1. Diarrhea, nausea, vomiting,

abdominal pain2. Hair loss

Apr 28, 2023 59muskuloskeletal2012

Page 60: (4). NSAID-musket2013

3. Bone marrow depression4. Peripheral neuritis5. Myopathy

Acute intoxication: burning throat pain, bloody diarrhea, shock, hematuria, oliguriaFatal ascending CNS depression

Apr 28, 2023 60muskuloskeletal2012

Page 61: (4). NSAID-musket2013

All can be used except aspirin, salicylates and tolmetin

Oxaprozin also increases uric acid excretion and should be avoided in urate renal stones

Apr 28, 2023 61muskuloskeletal2012

Page 62: (4). NSAID-musket2013

Probenecid (& sulfinpyrazone) Decrease body pool of uric acid by

increasing its excretionPharmacodynamics:

Uric acid is secreted and reabsorbed in the proximal renal tubules by active organic acid transport proteinsThese transport proteins are inhibited by probenecid, sulfinpyrazone and large doses of aspirin leading to decreased net reabsorption of uric acid Uric acid excretion

Apr 28, 2023 62muskuloskeletal2012

Page 63: (4). NSAID-musket2013

Therefore, the formation of uric acid renal stones may be increased. Thus fluid intake and alkalinization of urine is necessary to maintain urine flow and decrease precipitation of uric acid.

Pharmacokinetics:Probenecid is slowly metabolizedSulfinpyrazone is eliminated by the kidney

Apr 28, 2023 63muskuloskeletal2012

Page 64: (4). NSAID-musket2013

Adverse effects:1. GIT irritation (S > P)2. Skin rash and allergic

dermatitis (P > S)3. Nephrotic syndrome4. Aplastic anemia5. Renal stone formation

Apr 28, 2023 64muskuloskeletal2012

Page 65: (4). NSAID-musket2013

Inhibits xanthine oxidase and thus uric acid formation. It decreases plasma urate levels with a concurrent increase in the soluble xanthine and hypoxanthinePurine xanthine hypoxanthine uric acid

Pharmacokinetics: ~ 80 % absorbed after oral administration, metabolized also by xanthine oxidase to alloxanthine which is also an inhibitor of the enzyme

Apr 28, 2023 65muskuloskeletal2012

Page 66: (4). NSAID-musket2013

Uses:1. When uricosuric agents fail2. When urinary excretion of uric

acid is high3. Recurrent urate renal stone

formation4. To prevent massive uricosuria

following therapy of blood dyscrasia and cancer

Apr 28, 2023 66muskuloskeletal2012

Page 67: (4). NSAID-musket2013

Adverse effects:1. Acute attack of gouty arthritis

at the beginning of treatment which can be prevented by colchicine or NSAIDs

2. GIT: Nausea, vomiting, diarrhea3. Peripheral neuritis4. Necrotizing vasculitis5. Bone marrow depression

Apr 28, 2023 67muskuloskeletal2012

Page 68: (4). NSAID-musket2013

6. Hepatic toxicity7. Interstitial nephritis8. Allergic pruritic maculopapular

rash9. Exfoliative dermatitis10. CataractDrug interactions:

Inhibits the metabolism of mercaptopurine, azathioprine, warfarin, probenecid and cyclophosphamide

Apr 28, 2023 68muskuloskeletal2012

Page 69: (4). NSAID-musket2013

1. Sebutkan 2 contoh obat yang termasuk dalam NSAIDs, beserta mekanisme kerjanya

2. Sebutkan 2 efek samping yg sering tjd akibat pemakaian NSAIDs

3. Sebutkan 2 indikasi NSAIDs

Apr 28, 2023muskuloskeletal2012 69

Page 70: (4). NSAID-musket2013

Apr 28, 2023muskuloskeletal2012 70